Price History

Hover for the daily close. The dotted line marks the period open.

Compare MCRB with… →

MCRB Key Statistics

As of Sep 4, 2026

Trading

Open: $5.64
Previous Close: $5.64
Day's Range: 5.58–5.89
52-Week Range: 4.32–29.98
Volume: 36.40K
Beta: 0.21

Valuation

Market Cap: $57.46M
P/E Ratio: unprofitable
P/S ratio: 30.51
EPS (ttm): −2.42

Financials (FY)

Revenue (FY): $789.00K
Net Income (FY): $5.70M+4088.24%
Profit margin: 0.00%
Shares Outstanding: 10.04M
1-Year Return: −69.57%

Dividend and dates

Earnings Date: November 4, 2026estimated
Avg Volume: 89.81K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MCRB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+610.14%−75.00%−61.56%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−61.56%
2025	−10.47%
2024	−40.64%
2023	−75.00%
2022	−32.77%
2021	−66.00%
2020	+610.14%
2019	−23.67%
2018	−55.42%
2017	+2.42%
2016 (partial year)	+2.17%

As of September 4, 2026.

MCRB Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$789.00K	$5.70M	721.9%
2024	$0.00	$136.00K	—
2023	$0.00	−$113.72M	—
2022	$0.00	−$250.16M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$789.00K	−$5.76M	−$93.97M	$5.70M	721.9%
2024	$0.00	−$3.53M	−$121.32M	$136.00K	—
2023	$0.00	$0.00	−$195.10M	−$113.72M	—
2022	$0.00	$0.00	−$179.91M	−$250.16M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MCRB Valuation vs Biotechnology Median

Median of 656 stocks

Metric	MCRB	Biotechnology median	vs median
P/S ratio	30.51	15.26	100% above
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Seres Therapeutics, Inc. (MCRB) carries a market capitalisation of $57.46M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 66.

MCRB last closed at $5.72 on September 4, 2026. That is +$0.08 (+1.42%) against the previous close. The 52-week range on file runs from $4.32 to $29.98. The latest close sits 32.56% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $789.00K. The same year closed with net income of $5.70M. That is +4,088.24% against the prior fiscal year. Profit margin runs at 0%. Earnings per share on a trailing basis come to −2.42.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $789.00K in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 30.51 times revenue. On price-to-sales that is 99.91% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 0.22. Annualized volatility over the trailing 10 years is 152.76%. The trailing one-year price return is −69.57%. Measured over 10 years, that is −30.00% a year compounded.

Growth & Income

No dividend is on file for MCRB.

2026 is still running; the price is −61.56% year to date. Across the complete calendar years on file, 2020 returned +610.14% and 2023 returned −75.00%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Seres Therapeutics, Inc. (MCRB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Seres Therapeutics, Inc.	MCRB	$57.46M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Seres Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Seres Therapeutics, Inc.

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Visit website →

Seres Therapeutics, Inc. (MCRB) Stock Analysis